Prosecution Insights
Last updated: April 19, 2026
Application No. 18/379,776

SURGICAL TOOL WITH RELAXED FLEX CIRCUIT ARTICULATION

Non-Final OA §102§103
Filed
Oct 13, 2023
Examiner
MILLER, SERENITY A
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Cilag GmbH International
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
3y 1m
To Grant
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allow Rate
80 granted / 112 resolved
+1.4% vs TC avg
Strong +34% interview lift
Without
With
+34.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 1m
Avg Prosecution
26 currently pending
Career history
138
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
43.0%
+3.0% vs TC avg
§102
25.8%
-14.2% vs TC avg
§112
24.7%
-15.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 112 resolved cases

Office Action

§102 §103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 8-11, 13-14 and 16-19 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Goldman (US 8,251,948 B2). Regarding claim 8, Goldman discloses a treatment system (100, see Fig. 1A-2A) comprising: a tube (102) including a suction lumen (112); and a first closing member (128) and a second closing member (124) configured to close a part of a tubular organ, and the first closing member and the second closing member attached to the tube (see Fig. 1A): and a holding member (126) disposed between the first closing member and the second closing member, wherein a first end of the holding member is configured to contact with one of the first closing member and the second closing member (see Fig. 4A). Regarding claim 9, Goldman discloses the treatment system according to claim 8, wherein the holding member is expandable together with the first closing member and the second closing member (the balloons are independently inflatable, so it is understood they can be inflated simultaneously if desired, see col. 5, lines 42-53). Regarding claim 10, Goldman discloses the treatment system according to claim 8, wherein a maximum length in a radial direction of the tube when the holding member is expanded is not more than a maximum length in the radial direction when the first closing member and the second closing member are expanded to a maximum (when central balloon 126 is inflated, its length in the radial direction is not more than the length of the balloons 124, 128 in the radial direction, see Fig. 4B-4C). Regarding claim 11, Goldman discloses the treatment system according to claim 8, wherein the holding member is configured to be at least one of a linear member, a net, a stent, a balloon, and a twisted wire (the holding member taught by Goldman is a balloon, see col. 5, lines 39-42). Regarding claim 13, Goldman discloses the treatment system according to claim 8, wherein the tube includes a suction opening disposed between the first closing member and the second closing member (conduit 110 forms a suction opening between balloons 124 and 128, see Fig. 2A and col. 6, lines 21-28). Regarding claim 14, Goldman discloses the treatment system according to claim 8, wherein the first end of the holding member is configured to be connected to the first closing member and a second end of the holding member is connected to the second closing member (see Fig. 4A). Regarding claim 16, Goldman discloses the treatment system according to claim 8, wherein the first closing member is expandable at a first length in a radial direction of the tube, the second closing member is expandable at a second length in the radial direction, the holding member is expandable at a third length in the radial direction, and the third length of the holding member is equal to or less than the first length and the second length (when central balloon 126 is inflated, its length in the radial direction is not more than the length of the balloons 124, 128 in the radial direction, see Fig. 4B-4C). Regarding claim 17, Goldman discloses the treatment system according to claim 16, the holding member is expandable together with the first closing member and the second closing member (the balloons are independently inflatable, so it is understood they can be inflated simultaneously if desired, see col. 5, lines 42-53). Regarding claim 18, Goldman discloses the treatment system of claim 16, wherein the first closing member is provided distally relative to the second closing member (balloon 128 is distal to balloon 124, see Fig. 2A), the holding member has a first length in a longitudinal direction of the tube, a portion of the tube has a second length between a proximal end of the first closing member and a distal end of the second closing member, and the first length is longer than the second length (the entire length of the balloon 126 is longer than an arbitrarily selected length of the catheter body 102 extending between the balloons 124 and 128, see Fig. 4A). Regarding claim 19, Goldman discloses the treatment system according to claim 8, wherein the first closing member and the second closing member are balloons (see col. 5, lines 39-42). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 20 is rejected under 35 U.S.C. 103 as being unpatentable over Goldman, as applied to claim 8 above, further in view of Mohl et al (US 4,934,996). Regarding claim 20, Goldman discloses the treatment system according to claim 8, but fails to expressly teach a suction pump configured to suction fluid from the suction lumen. It is noted that Goldman discloses fluid flowing into and out of the balloons through conduit 112 (i.e., the suction lumen) for inflation/deflation of the balloons (see col. 6, lines 21-37). Goldman simply fails to expressly teach the mechanism for supplying/removing fluid through conduit 112. Mohl, in the same field of art, teaches a related balloon catheter, having a pump for inflating and deflating the balloon (see col. 1, lines 41-46). It would have been obvious to one of ordinary skill in the art, before the effective filing date of the claimed invention, to modify the treatment system of Goldman so that it includes a suction pump, as taught by Mohl, since doing so would have provided the treatment system with a mechanism for inflating and deflating the balloons. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SERENITY MILLER whose telephone number is (571)272-1155. The examiner can normally be reached Monday-Friday 8:00am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Elizabeth Houston can be reached at (571)272-7134. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SERENITY A MILLER/Examiner, Art Unit 3771 /ELIZABETH HOUSTON/Supervisory Patent Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Oct 13, 2023
Application Filed
Mar 07, 2026
Non-Final Rejection — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12582425
CATHETER INCLUDING A RADIOPAQUE EXPANDABLE MEMBER
2y 5m to grant Granted Mar 24, 2026
Patent 12551227
SURGICAL INSTRUMENT, TOOL DEVICE FOR SUCH A SURGICAL INSTRUMENT, AND METHOD FOR PRODUCING SUCH A TOOL DEVICE
2y 5m to grant Granted Feb 17, 2026
Patent 12533137
MEDICAL DEVICE WITH ENHANCED SHAPE CHARACTERISTICS
2y 5m to grant Granted Jan 27, 2026
Patent 12514592
APPARATUS FOR DISPLACEMENT OF BLOOD TO MITIGATE PERIPHERAL NERVE NEUROPATHY
2y 5m to grant Granted Jan 06, 2026
Patent 12502199
DURA ELEVATING AND CUTTING APPARATUS
2y 5m to grant Granted Dec 23, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+34.0%)
3y 1m
Median Time to Grant
Low
PTA Risk
Based on 112 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month